

## 1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>256.4</b>	<b>+12.9%</b>	<b>100%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>100%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>100%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>100%</b>	<b>967.4</b>	<b>15.3</b>	<b>+1.6%</b>
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
<b>Operating Income</b>	<b>24%</b>	<b>61.1</b>	<b>+128.1%</b>	<b>12%</b>	<b>29.0</b>	<b>+20.6%</b>	<b>12%</b>	<b>30.5</b>	<b>-22.2%</b>	<b>1%</b>	<b>1.5</b>	<b>-72.2%</b>	<b>13%</b>	<b>122.1</b>	<b>26.6</b>	<b>+27.9%</b>
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
<b>Ordinary Income</b>	<b>27%</b>	<b>70.1</b>	<b>+877.7%</b>	<b>9%</b>	<b>22.6</b>	<b>-50.0%</b>	<b>15%</b>	<b>38.0</b>	<b>-1.1%</b>	<b>1%</b>	<b>1.2</b>	<b>-90.7%</b>	<b>14%</b>	<b>131.8</b>	<b>28.6</b>	<b>+27.8%</b>
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
<b>Net Income</b>	<b>13%</b>	<b>33.1</b>	<b>-</b>	<b>8%</b>	<b>19.1</b>	<b>-24.1%</b>	<b>11%</b>	<b>27.5</b>	<b>+33.8%</b>	<b>-4%</b>	<b>-9.5</b>	<b>-</b>	<b>7%</b>	<b>70.1</b>	<b>28.3</b>	<b>+67.5%</b>
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

## 2. Currency Rate (FY2010)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72 -7.14
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13 -18.03
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93 -0.02

### 3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	<b>201.6</b>	<b>+2.1%</b>	100%	<b>198.8</b>	<b>-4.0%</b>	100%	<b>213.7</b>	<b>-2.4%</b>	100%	<b>181.3</b>	<b>-0.3%</b>	100%	<b>795.5</b>	<b>-10.0</b>	<b>-1.2%</b>
Cost of sales	22%	44.9	-1.1%	27%	54.4	+0.1%	26%	55.0	-1.1%	26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%	73%	144.4	-5.4%	74%	158.8	-2.9%	74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%	61%	121.2	-4.2%	60%	127.7	+2.7%	73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%	22%	43.5	-6.9%	24%	50.6	+12.0%	27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%	39%	77.7	-2.6%	36%	77.1	-2.6%	45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
<b>Operating Income</b>	22%	<b>43.3</b>	<b>+44.0%</b>	12%	<b>23.2</b>	<b>-11.6%</b>	15%	<b>31.1</b>	<b>-20.6%</b>	1%	<b>2.3</b>	<b>-1422.3%</b>	13%	<b>99.8</b>	<b>4.6</b>	<b>+4.8%</b>
Non-operating income		1.8			1.9			2.6			0.9			7.2	0.2	
Non-operating expenses		1.7			2.0			-0.1			3.4			7.0	0.9	
<b>Ordinary Income</b>	22%	<b>43.4</b>	<b>+34.8%</b>	12%	<b>23.1</b>	<b>-12.6%</b>	16%	<b>33.7</b>	<b>-12.9%</b>	0%	<b>-0.2</b>	-	13%	<b>100.0</b>	<b>3.8</b>	<b>+4.0%</b>
Extraordinary income		0.8			3.8			1.4			4.3			10.2	5.7	
Extraordinary losses		4.2			1.0			0.7			15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%	13%	25.9	-1.6%	16%	34.4	-8.6%	-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7			7.5			8.5			-3.1			30.6	-23.7	
Minority interests																
<b>Net Income</b>	11%	<b>22.3</b>	<b>+122.8%</b>	9%	<b>18.3</b>	<b>+39.4%</b>	12%	<b>26.0</b>	<b>+30.0%</b>	-4%	<b>-7.8</b>	-	7%	<b>58.8</b>	<b>23.9</b>	<b>+68.6%</b>
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	<b>54.9</b>	<b>+84.9%</b>	100%	<b>43.8</b>	<b>+20.1%</b>	100%	<b>35.5</b>	<b>-1.4%</b>	100%	<b>38.9</b>	<b>-12.6%</b>	100%	<b>173.1</b>	<b>26.4</b>	<b>+18.0%</b>
Cost of sales	35%	19.2	+12.0%	46%	20.0	-1.8%	55%	19.5	-1.7%	54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%	54%	23.7	+48.0%	45%	16.0	-1.1%	46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%	39%	17.1	+2.9%	43%	15.4	+5.3%	43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%	7%	3.0	+32.0%	8%	2.8	+19.0%	7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%	32%	14.1	-1.8%	35%	12.5	+2.6%	36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
<b>Operating Income</b>	35%	<b>19.3</b>	<b>-1171.9%</b>	15%	<b>6.6</b>	<b>-1214.7%</b>	2%	<b>0.6</b>	<b>-60.0%</b>	3%	<b>1.1</b>	<b>-83.9%</b>	16%	<b>27.7</b>	<b>21.4</b>	<b>+338.8%</b>
Non-operating income		10.0			-3.0			4.9			4.2			16.2	-5.0	
Non-operating expenses		1.1			2.7			0.1			0.1			3.9	-10.5	
<b>Ordinary Income</b>	52%	<b>28.3</b>	<b>-220.1%</b>	2%	<b>0.9</b>	<b>-95.4%</b>	16%	<b>5.5</b>	<b>+374.9%</b>	14%	<b>5.3</b>	<b>-65.1%</b>	23%	<b>40.0</b>	<b>27.0</b>	<b>+207.8%</b>
Extraordinary income		0.0			5.2			0.0			-0.1			5.1	3.8	
Extraordinary losses		0.7			0.1			1.5			6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%	14%	6.0	-70.2%	11%	4.0	+249.7%	-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2			1.5			0.1			2.4			13.2	3.4	
Minority interests		0.1			0.1			0.1			0.1			0.3	0.1	
<b>Net Income</b>	33%	<b>18.4</b>	-	10%	<b>4.5</b>	<b>-68.3%</b>	11%	<b>3.8</b>	-	-9%	<b>-3.3</b>	-	14%	<b>23.3</b>	<b>19.1</b>	<b>+456.4%</b>
<b>Inter-segment Transactions</b>																
<b>Net sales</b>		<b>-0.1</b>			<b>-0.1</b>			<b>-0.1</b>			<b>-0.9</b>			<b>-1.2</b>		
Cost of sales		0.0			0.0			0.1			0.0			0.1		
Gross Profit		-0.1			-0.1			-0.2			-0.9			-1.3		
SG&A expenses		1.5			0.7			1.0			1.0			4.1		
R&D expenses		0.0			-0.8			-0.4			-0.4			-1.7		
Other expenses		1.5			1.5			1.4			1.4			5.8		
<b>Operating Income</b>		<b>-1.5</b>			<b>-0.7</b>			<b>-1.2</b>			<b>-1.9</b>			<b>-5.4</b>		
Non-operating income		0.0			-0.7			-0.1			0.5			-0.2		
Non-operating expenses					0.1			0.0			2.5			2.6		
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.3</b>			<b>-3.9</b>			<b>-8.2</b>		
Extraordinary income		0.0			-2.2			-0.5			0.1			-2.5		
Extraordinary losses					0.2			0.0			-5.2			-5.0		
Income before income taxes and minority interests		-1.5			-3.9			-1.7			1.4			-5.7		
Income taxes		-0.3			-0.8			-0.6			-0.2			-2.0		
Minority interests		6.4			0.7			1.1			-0.1			8.2		
<b>Net Income</b>		<b>-7.6</b>			<b>-3.8</b>			<b>-2.2</b>			<b>1.6</b>			<b>-12.0</b>		

#### 4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>256.4</b>	<b>+12.9%</b>	<b>242.5</b>	<b>-0.4%</b>	<b>249.2</b>	<b>-2.3%</b>	<b>219.3</b>	<b>-3.2%</b>	<b>967.4</b>	<b>+1.6%</b>
<b>Japan Company (domestic sales)</b>	<b>105.3</b>	<b>+0.6%</b>	<b>103.0</b>	<b>-1.7%</b>	<b>116.8</b>	<b>-1.4%</b>	<b>91.0</b>	<b>+7.6%</b>	<b>416.0</b>	<b>+0.9%</b>
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.3</b>	<b>-2.7%</b>	<b>11.7</b>	<b>-12.9%</b>	<b>13.2</b>	<b>+9.1%</b>	<b>10.6</b>	<b>+23.2%</b>	<b>44.8</b>	<b>+2.6%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.6</b>	<b>+1.7%</b>	<b>33.9</b>	<b>+1.2%</b>	<b>34.6</b>	<b>+0.6%</b>	<b>28.4</b>	<b>-11.6%</b>	<b>130.5</b>	<b>-1.9%</b>
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>14.7</b>	<b>+10.4%</b>	<b>13.7</b>	<b>+1.3%</b>	<b>11.5</b>	<b>-8.5%</b>	<b>14.0</b>	<b>+10.5%</b>	<b>53.9</b>	<b>+3.5%</b>
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
<b>Daiichi Sankyo Europe GmbH</b>	<b>14.8</b>	<b>-14.6%</b>	<b>16.6</b>	<b>-10.0%</b>	<b>18.1</b>	<b>-5.0%</b>	<b>16.9</b>	<b>-17.2%</b>	<b>66.4</b>	<b>-11.7%</b>
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
<b>Asia, South and Central America (ASCA)</b>	<b>5.9</b>	<b>+12.7%</b>	<b>7.1</b>	<b>+12.8%</b>	<b>6.8</b>	<b>+3.3%</b>	<b>7.6</b>	<b>-0.4%</b>	<b>27.4</b>	<b>+6.4%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
<b>Ranbaxy Laboratories Limited</b>	<b>54.8</b>	<b>+84.7%</b>	<b>43.7</b>	<b>+19.9%</b>	<b>35.4</b>	<b>-1.6%</b>	<b>38.0</b>	<b>-14.5%</b>	<b>171.9</b>	<b>+17.3%</b>
<b>Others</b>	<b>18.0</b>	<b>+25.6%</b>	<b>12.8</b>	<b>-25.1%</b>	<b>12.7</b>	<b>-20.2%</b>	<b>12.8</b>	<b>-20.0%</b>	<b>56.3</b>	<b>-11.1%</b>
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Effient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

**[Reference] Sales in Local Currency (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daichi Sankyo, Inc. (US)</b>	<b>365</b>	<b>+7.6%</b>	<b>394</b>	<b>+10.2%</b>	<b>422</b>	<b>+10.3%</b>	<b>342</b>	<b>-3.3%</b>	<b>1,522</b>	<b>+6.3%</b>
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>160</b>	<b>+16.7%</b>	<b>159</b>	<b>+10.6%</b>	<b>142</b>	<b>+1.2%</b>	<b>168</b>	<b>+20.1%</b>	<b>629</b>	<b>+12.1%</b>
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
<b>Daichi Sankyo Europe GmbH</b>	<b>126</b>	<b>-3.2%</b>	<b>149</b>	<b>+8.3%</b>	<b>161</b>	<b>+12.1%</b>	<b>150</b>	<b>-7.0%</b>	<b>587</b>	<b>+2.3%</b>
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>28</b>	<b>+76.3%</b>	<b>21</b>	<b>+17.1%</b>	<b>19</b>	<b>+4.6%</b>	<b>21</b>	<b>-9.0%</b>	<b>89</b>	<b>+18.5%</b>

**5. Sales of Global Products (FY2010)**

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>60.2</b>	<b>+7.6%</b>	<b>61.4</b>	<b>+3.4%</b>	<b>65.7</b>	<b>+1.6%</b>	<b>54.2</b>	<b>-7.0%</b>	<b>241.5</b>	<b>+1.4%</b>
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
<b>Levofloxacin</b>	<b>17.0</b>	<b>-14.3%</b>	<b>16.9</b>	<b>-28.0%</b>	<b>18.1</b>	<b>-18.3%</b>	<b>17.2</b>	<b>-21.1%</b>	<b>69.1</b>	<b>-20.7%</b>
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
<b>Pravastatin</b>	<b>11.9</b>	<b>-19.1%</b>	<b>11.8</b>	<b>-21.5%</b>	<b>11.6</b>	<b>-21.8%</b>	<b>9.6</b>	<b>-8.3%</b>	<b>44.9</b>	<b>-18.4%</b>
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.8</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>1.5</b>	<b>-</b>	<b>2.0</b>	<b>-</b>	<b>5.2</b>	<b>+889.6%</b>
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Effient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

## 1. Summary of Consolidated Income Statement (FY2009)

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	<b>100%</b>	<b>227.1</b>	<b>+11.5%</b>	<b>100%</b>	<b>243.4</b>	<b>+20.2%</b>	<b>100%</b>	<b>255.1</b>	<b>+15.3%</b>	<b>100%</b>	<b>226.4</b>	<b>+5.6%</b>	<b>100%</b>	<b>952.1</b>	<b>110.0</b>	<b>+13.1%</b>
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
<b>Operating Income</b>	<b>12%</b>	<b>26.8</b>	<b>-33.1%</b>	<b>10%</b>	<b>24.1</b>	<b>+11.5%</b>	<b>15%</b>	<b>39.2</b>	<b>+7.6%</b>	<b>2%</b>	<b>5.4</b>	<b>-</b>	<b>10%</b>	<b>95.5</b>	<b>6.6</b>	<b>+7.5%</b>
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
<b>Ordinary Income</b>	<b>3%</b>	<b>7.2</b>	<b>-82.5%</b>	<b>19%</b>	<b>45.1</b>	<b>+140.0%</b>	<b>15%</b>	<b>38.4</b>	<b>+14.4%</b>	<b>6%</b>	<b>12.5</b>	<b>-</b>	<b>11%</b>	<b>103.1</b>	<b>47.9</b>	<b>+86.9%</b>
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
<b>Net Income</b>	<b>-3%</b>	<b>-6.4</b>	<b>-</b>	<b>10%</b>	<b>25.1</b>	<b>+182.7%</b>	<b>8%</b>	<b>20.6</b>	<b>-</b>	<b>1%</b>	<b>2.6</b>	<b>-96.8%</b>	<b>4%</b>	<b>41.9</b>	<b>257.4</b>	<b>-</b>
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

## 2. Currency Rate (FY2009)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86 -7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16 -12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95 -0.05

### 3. Segment Information (FY2009)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
<b>Net sales</b>	100%	<b>197.4</b>	<b>-3.1%</b>	100%	<b>207.0</b>	<b>+2.2%</b>	100%	<b>219.1</b>	<b>-1.0%</b>	100%	<b>181.9</b>	<b>+3.4%</b>	100%	<b>805.5</b>	<b>1.9</b>	<b>+0.2%</b>
Cost of sales	23%	45.4	-6.7%	26%	54.3	+10.9%	25%	55.6	+4.6%	26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%	74%	152.7	-0.6%	75%	163.5	-2.8%	74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%	61%	126.5	-4.2%	57%	124.3	-1.5%	74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%	23%	46.7	+2.8%	21%	45.2	-3.5%	28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%	39%	79.8	-7.8%	36%	79.1	-0.3%	46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
<b>Operating Income</b>	15%	<b>30.0</b>	<b>-24.9%</b>	13%	<b>26.2</b>	<b>+21.3%</b>	18%	<b>39.1</b>	<b>-6.7%</b>	0%	<b>-0.2</b>	-	12%	<b>95.2</b>	<b>-12.4</b>	<b>-11.5%</b>
Non-operating income		2.9			2.0			1.8			0.4			7.1	-3.8	
Non-operating expenses		0.8			1.8			2.2			1.4			6.1	-13.9	
<b>Ordinary Income</b>	16%	<b>32.2</b>	<b>-21.3%</b>	13%	<b>26.4</b>	<b>+40.5%</b>	18%	<b>38.7</b>	<b>-0.8%</b>	-1%	<b>-1.1</b>	-	12%	<b>96.1</b>	<b>-2.2</b>	<b>-2.3%</b>
Extraordinary income		2.1			0.2			1.5			0.8			4.6	0.9	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%	13%	26.3	+54.4%	17%	37.7	+0.5%	-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6			13.1			17.7			-0.2			54.3	17.8	
Minority interests																
<b>Net Income</b>	5%	<b>10.0</b>	<b>-60.1%</b>	6%	<b>13.2</b>	<b>+48.0%</b>	9%	<b>20.0</b>	<b>-27.9%</b>	-5%	<b>-8.3</b>	-	4%	<b>34.8</b>	<b>-15.1</b>	<b>-30.2%</b>
<b>Ranbaxy Group</b>																
<b>Net sales</b>	100%	<b>29.7</b>		100%	<b>36.4</b>		100%	<b>36.0</b>		100%	<b>44.5</b>	<b>+15.1%</b>	100%	<b>146.7</b>	<b>108.0</b>	
Cost of sales	58%	17.1		56%	20.4		55%	19.8		41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6		44%	16.0		45%	16.2		59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4		46%	16.6		41%	14.6		43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1		6%	2.3		7%	2.4		8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3		39%	14.3		34%	12.2		36%	15.8	+5.6%	37%	54.6	39.6	
<b>Operating Income</b>	-6%	<b>-1.8</b>		-2%	<b>-0.6</b>		4%	<b>1.6</b>		16%	<b>7.1</b>	<b>+1119.4%</b>	4%	<b>6.3</b>	<b>5.7</b>	
Non-operating income		1.0			9.0			2.5			8.7			21.1	19.7	
Non-operating expenses		22.7			-11.9			2.9			0.7			14.5	-11.5	
<b>Ordinary Income</b>	-79%	<b>-23.5</b>		56%	<b>20.2</b>		3%	<b>1.2</b>		34%	<b>15.1</b>	-	9%	<b>13.0</b>	<b>36.9</b>	
Extraordinary income		0.0			0.0			0.0			1.3			1.3	1.2	
Extraordinary losses								0.0			0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5		56%	20.2		3%	1.1		37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6			6.0			1.3			9.2			9.8	17.7	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.1	
<b>Net Income</b>	-57%	<b>-16.9</b>		39%	<b>14.2</b>		-1%	<b>-0.2</b>		16%	<b>7.1</b>	-	3%	<b>4.2</b>	<b>20.4</b>	
<b>Inter-segment Transactions</b>																
<b>Net sales</b>																
Cost of sales																
Gross Profit																
SG&A expenses		1.5			1.5			1.5			1.5			6.0		
R&D expenses																
Other expenses		1.5			1.5			1.5			1.5			6.0		
<b>Operating Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.5</b>			<b>-1.5</b>			<b>-6.0</b>		
Non-operating income																
Non-operating expenses																
<b>Ordinary Income</b>		<b>-1.5</b>			<b>-1.5</b>			<b>-1.5</b>			<b>-1.5</b>			<b>-6.0</b>		
Extraordinary income																
Extraordinary losses																
Income before income taxes and minority interests		-1.5			-1.5			-1.5			-1.5			-6.0		
Income taxes		7.0			-6.4			-3.0			-11.8			-14.1		
Minority interests		-8.9			7.1			0.7			6.5			5.3		
<b>Net Income</b>		<b>0.5</b>			<b>-2.3</b>			<b>0.8</b>			<b>3.8</b>			<b>2.8</b>		

#### 4. Sales by Business Units (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Consolidated Net Sales</b>	<b>227.1</b>	<b>11.5%</b>	<b>243.4</b>	<b>20.2%</b>	<b>255.1</b>	<b>15.3%</b>	<b>226.4</b>	<b>5.6%</b>	<b>952.1</b>	<b>13.1%</b>
<b>Japan Company (domestic sales)</b>	<b>104.6</b>	<b>3.7%</b>	<b>104.8</b>	<b>5.3%</b>	<b>118.4</b>	<b>-1.4%</b>	<b>84.5</b>	<b>-1.9%</b>	<b>412.3</b>	<b>1.4%</b>
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
<b>Daiichi Sankyo Healthcare (OTC)</b>	<b>9.5</b>	<b>-6.9%</b>	<b>13.5</b>	<b>-2.1%</b>	<b>12.1</b>	<b>-8.2%</b>	<b>8.6</b>	<b>-14.1%</b>	<b>43.7</b>	<b>-7.4%</b>
<b>Daiichi Sankyo, Inc. (US)</b>	<b>33.0</b>	<b>-11.2%</b>	<b>33.5</b>	<b>5.6%</b>	<b>34.4</b>	<b>5.8%</b>	<b>32.1</b>	<b>15.2%</b>	<b>133.0</b>	<b>2.9%</b>
Olmесartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>13.4</b>	<b>-1.1%</b>	<b>13.5</b>	<b>-0.4%</b>	<b>12.6</b>	<b>-6.4%</b>	<b>12.7</b>	<b>18.9%</b>	<b>52.1</b>	<b>1.9%</b>
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
<b>Daiichi Sankyo Europe GmbH</b>	<b>17.3</b>	<b>14.1%</b>	<b>18.4</b>	<b>-0.4%</b>	<b>19.1</b>	<b>6.1%</b>	<b>20.4</b>	<b>9.7%</b>	<b>75.2</b>	<b>7.1%</b>
Olmесartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
<b>Asia, South and Central America (ASCA)</b>	<b>5.3</b>	<b>0.5%</b>	<b>6.3</b>	<b>7.1%</b>	<b>6.6</b>	<b>11.7%</b>	<b>7.7</b>	<b>27.5%</b>	<b>25.8</b>	<b>12.1%</b>
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
<b>Ranbaxy Laboratories Limited</b>	<b>29.7</b>	<b>-</b>	<b>36.4</b>	<b>-</b>	<b>36.0</b>	<b>-</b>	<b>44.4</b>	<b>14.9%</b>	<b>146.6</b>	<b>-</b>
<b>Others</b>	<b>14.4</b>	<b>-33.2%</b>	<b>17.1</b>	<b>-13.6%</b>	<b>15.9</b>	<b>-12.3%</b>	<b>16.0</b>	<b>-3.0%</b>	<b>63.4</b>	<b>-16.5%</b>
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Effient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

**[Reference] Sales in Local Currency (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
<b>Daiichi Sankyo, Inc. (US)</b>	<b>339</b>	<b>-4.6%</b>	<b>357</b>	<b>21.7%</b>	<b>382</b>	<b>13.4%</b>	<b>354</b>	<b>18.0%</b>	<b>1,433</b>	<b>11.4%</b>
Olmesartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
<b>Luitpold Pharmaceuticals, Inc. (US)</b>	<b>137</b>	<b>6.2%</b>	<b>144</b>	<b>14.5%</b>	<b>140</b>	<b>1.1%</b>	<b>140</b>	<b>21.4%</b>	<b>561</b>	<b>10.3%</b>
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
<b>Daiichi Sankyo Europe GmbH</b>	<b>131</b>	<b>40.6%</b>	<b>138</b>	<b>20.8%</b>	<b>144</b>	<b>5.9%</b>	<b>161</b>	<b>9.8%</b>	<b>574</b>	<b>17.1%</b>
Olmesartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmetec/Olmetec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
<b>Ranbaxy Laboratories Limited</b>	<b>16</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>18</b>	<b>-</b>	<b>23</b>	<b>17.9%</b>	<b>75</b>	<b>-</b>

**5. Sales of Global Products (FY2009)**

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
<b>Olmesartan</b>	<b>56.0</b>	<b>10.5%</b>	<b>59.4</b>	<b>10.2%</b>	<b>64.7</b>	<b>12.3%</b>	<b>58.3</b>	<b>19.0%</b>	<b>238.3</b>	<b>12.9%</b>
Olmetec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmetec/Olmetec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
<b>Levofloxacin</b>	<b>19.8</b>	<b>-23.2%</b>	<b>23.5</b>	<b>-0.3%</b>	<b>22.1</b>	<b>-14.2%</b>	<b>21.8</b>	<b>-3.5%</b>	<b>87.2</b>	<b>-10.7%</b>
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
<b>Pravastatin</b>	<b>14.7</b>	<b>-8.5%</b>	<b>15.0</b>	<b>-5.2%</b>	<b>14.8</b>	<b>-10.8%</b>	<b>10.5</b>	<b>-14.9%</b>	<b>55.0</b>	<b>-9.6%</b>
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
<b>Prasugrel (alliance revenue)</b>	<b>0.0</b>	<b>-</b>	<b>1.0</b>	<b>-</b>	<b>0.3</b>	<b>-</b>	<b>-0.7</b>	<b>-</b>	<b>0.5</b>	<b>-</b>
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Effient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-